Clinical Trials | February 23, 2026
Dr. Reddy’s secures first-mover advantage with FDA review of Orencia biosimilar
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
